NCT00463021

A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection

A Phase 4, Multi Center, Open-Label, Randomized Study to Determine Clinically Appropriate Doses of Hectorol® (Doxercalciferol Capsules) When Converting From Zemplar® (Paricalcitol Injection) for the Treatment of Secondary Hyperparathyroidism in Stage 5 Chronic Kidney Disease (CKD) Subjects on Hemodialysis.

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 36 (estimated)
• Sponsor: Genzyme, a Sanofi Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Protocol HECT00306 aims to determine clinically appropriate doses of Hectorol (doxercalciferol capsules) when converting from Zemplar (paricalcitol injection) for the treatment of secondary hyperparathyroidism in Stage 5 chronic kidney disease on hemodialysis.

Conditions

• Secondary Hyperparathyroidism

Interventions

Type	Name	Description
DRUG	Hectorol (doxercalciferol capsules)
DRUG	Zemplar (paricalcitol injection)

Timeline

• Start date: 2007-04-01
• Completion: 2007-12-01
• First posted: 2007-04-19
• Last updated: 2015-05-05

Locations

8 sites across 1 country: United States